BCRX

Over the past six months (March 2026 - September 2026), BioCryst Pharmaceuticals' stock experienced a significant daily increase of +13.1% on March 16, 2026, and another +7.67% increase on May 27, 2026. The company held its First Quarter 2026 Earnings Call on May 6, 2026, and participated in the Jefferies Global Healthcare Conference on June 3, 2026. On July 15, 2026, the stock saw a -3.39% change following a new appointment. BioCryst reported strong Second Quarter 2026 Financial Results on August 5, 2026, with revenue surging 34% year over year to $218.3 million and a $98.5 million GAAP operating profit, also holding its earnings call. On August 25, 2026, Japan's approval of ORLADEYO for pediatric HAE patients led to a modest stock increase. The company announced a presentation at an upcoming investor conference on September 1, 2026. On September 10, 2026, RBC Capital downgraded the stock from Outperform to Sector Perform and cut its target price from $13 to $11 due to competitive pressure on ORLADEYO, resulting in a 7.3% stock drop. BioCryst presented at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.